TO THE EDITOR: I read "Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets" published July 2015 by Das et al. 1 This article is interesting because it outlines the role that inflammation plays in the pathogenesis of diabetic macular edema (DME) and discusses the novel therapies in this disease area. Das et al refer to the efficacy and safety of the fluocinolone acetonide (FAc) implant (ILUVIEN), which is licensed for the treatment of DME in a number of European countries and the United States. However, the author does not present the data relating to ILUVIEN specifically (with a release rate of 0.2 mg FAc per day 2 ), nor do they outline the differences between licensed indications in Europe and the United States.
In Europe, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME, considered insufficiently responsive to available therapies. 3 In the United States, it is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant increase in intraocular pressure (IOP). 3 In Europe, the license is based on data achieved at 36 months in the FAME trials 2 (FAME A and B) and in the United States, the license is based on the primary efficacy endpoint at 24 months. 2, 3 Further points need to be considered because they are potentially misleading and are addressed below.
First, Das et al state that "almost all patients receiving fluocinolone acetonide had cataract formation." Table 1 shows the rate of cataract formation for FAc implant ranged between 86.0% versus 51.5% and 81.7% versus 50.4% (0.2 mg FAc vs sham control; chronic DME and DME groups, respectively) depending on the population analyzed (Table 1) with the relative differences being 34.5% for chronic DME and 31.3% for DME. This relative difference being lower than the difference (47.5%) reported by Boyer et al. 4 Similarly for cataract extraction, where the differences between treatment and sham control were: ILUVIEN, 48.7% in chronic DME and 52.7% in DME; and Ozurdex, 52.0% ( Table 1) .
The second point relates to the incidence of rises in IOP and Das et al state that "The dexamethasone implant had a lower incidence of increases in IOP compared with the fluocinolone implant study" and then present the data for the rates of IOP-lowering surgery relating to 0.5 mg FAc per day, which is not the licensed dose. 2 and shows the percentage of patients treated with IOP-lowering drops was similar.
Das et al also mention that "only 0.3% to 0.6% of treated patients required incisional glaucoma surgery in the dexamethasone implant study." It is important to counterbalance by the fact that, in the MEAD trial, 4 the number of patients exiting the trial owing to an adverse event was higher than in the FAME trial (11.1% vs 2.7%, respectively), which could explain the lower rate of IOPlowering surgeries reported (Table 1) .
Das et al propose a mechanism for differences in the incidence of side effects and state that "Dexamethasone is less lipophilic and accumulates in the trabecular meshwork and lens less than fluocinolone or triamcinolone, which explains the lower incidence of side effects with dexamethasone." This is based on the work by Thakur et al, 5 but the validity of the findings from this group has been challenged in a Notice of Concern. 6 Thus, to date, there is a paucity of clinical trial data comparing the long-term safety of corticosteroids in DME and a lack of data to support the above suggested mechanism. The FAME trials were performed under a single protocol as randomized, double-masked, sham injection-controlled, parallel-group, multicenter studies conducted over a 36-month period and included a preplanned subgroup analysis to assess efficacy in chronic DME patients Primary endpoint
The primary endpoint for these studies at the end of 36 months was the average change in BCVA from baseline with one of the trials failing to reach its primary endpoint.
The primary endpoint in the FAME trials was 24 months. The secondary endpoint was at 36 months (and the basis for the license and indication approved in Europe). Both FAME trials independently met their primary efficacy endpoints of 15 letter improvement in BCVA over baseline. BCVA ¼ best-corrected visual acuity; DEX ¼ dexamethasone; DME ¼ diabetic macular edema; FAc ¼ Fluocinolone acetonide; IOP ¼ intraocular pressure. *Conclusions from these comparisons is difficult as data originates from two separate trials. Meaning that the benefit-to-risk profile for each trial needs to be considered. y Average change from baseline and calculated using an area under the curve approach.
z In patients previously treated with an ocular steroid injection, none underwent IOP-lowering surgery and all IOP-lowering surgeries in subjects treated with ILUVIEN occurred in patients having no history of ocular steroid injection.
